




RealRate

PHARMACEUTICAL 2026

Arcutis Biotherapeutics Inc
Rank 80 of 178



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Arcutis Biotherapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcutis Biotherapeutics Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 68% points. The greatest weakness of Arcutis Biotherapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 244%, being 14% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	411,232
Cost of Goods Sold	36,695
Intangible Assets	14,812
Liabilities, Current	129,838
Liabilities, Non-Current	113,656
Other Assets	5,886
Other Compr. Net Income	-37
Other Expenses	13,254
Other Liabilities	0
Other Net Income	9,340
Other Revenues	376,072
Property and Equipment	1,043
Research and Development	77,051
Selling, General and Administrative Expense	274,553

Output Variable	Value in 1000 USD
Assets	432,973
Liabilities	243,494
Expenses	401,553
Revenues	376,072
Stockholders Equity	189,479
Net Income	-16,141
Comprehensive Net Income	-16,160
BaseVar	731,734
ECR before LimitedLiability	117%
Economic Capital Ratio	244%